MedPath

Serum Institute of India Pvt Ltd.

Serum Institute of India Pvt Ltd. logo
🇮🇳India
Ownership
Subsidiary
Established
1996-01-01
Employees
1K
Market Cap
-
Website
http://www.seruminstitute.com

Clinical Trials

72

Active:9
Completed:49

Trial Phases

5 Phases

Phase 1:20
Phase 2:15
Phase 3:19
+2 more phases

Drug Approvals

7

PHILIPPINES:7

Drug Approvals

SII TD-VAC

Approval Date
Jul 14, 2025
PHILIPPINES

None

Approval Date
Jul 14, 2025
PHILIPPINES

GENVAC-B

Approval Date
Jul 14, 2025
PHILIPPINES

SII MR VAC

Approval Date
Jul 14, 2025
PHILIPPINES

SII-Onco-BCG

Approval Date
Jul 14, 2025
PHILIPPINES

None

Approval Date
Jul 14, 2025
PHILIPPINES

Repoitin 4000

Approval Date
Jul 14, 2025
PHILIPPINES

Clinical Trials

Distribution across different clinical trial phases (70 trials with phase data)• Click on a phase to view related trials

Phase 1
20 (28.6%)
Phase 3
19 (27.1%)
Phase 2
15 (21.4%)
phase_2_3
8 (11.4%)
Phase 4
5 (7.1%)
Not Applicable
2 (2.9%)
phase_1_2
1 (1.4%)

Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults

Not Applicable
Not yet recruiting
Conditions
Prevention of Malaria Transmission and Clinical Malaria
Interventions
Biological: 10µg of R21 with 50µg Matrix-M1
Biological: 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation
Biological: Conjugated Pfs230D1 Vaccine (Pfs230D1-CRM197) For Bedside Mixing
Biological: R21 Malaria Vaccine (Recombinant) For Bedside Mixing
Biological: MATRIX-M1 (Adjuvant) For Bedside Mixing
First Posted Date
2025-08-29
Last Posted Date
2025-08-29
Lead Sponsor
Serum Institute of India Pvt. Ltd.
Target Recruit Count
1200
Registration Number
NCT07147400
Locations
🇲🇱

University of Science, Technique and Technology of Bamako (Usttb), Bamako, Mali

An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine

Recruiting
Conditions
Malaria,Falciparum
Morality
First Posted Date
2025-06-08
Last Posted Date
2025-08-13
Lead Sponsor
Serum Institute of India Pvt. Ltd.
Target Recruit Count
2308
Registration Number
NCT07009847
Locations
🇧🇫

Unité de Recherche Clinique de Nanoro (URCN), Institut de Recherche en Sciences de la Santé, Direction Régionale du Centre-Ouest (IRSS-DRCO), Bousse, Boussé, Burkina Faso

🇨🇮

Centre de Recherche et de Lutte contre le Paludisme Institut National de Santé Publique, boulevard Nangui Abrogoua près État Major des Armées, Toumodi, Côte D'Ivoire

🇳🇬

University of Ilorin Department of Pediatrics University of Ilorin Teaching Hospital, Ilorin, Nigeria, Yenagoa, Bayesla, Nigeria

and more 2 locations

Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

Phase 1
Active, not recruiting
Conditions
Prevention of Malaria Transmission and Clinical Malaria
Interventions
Biological: Pfs230D1-CRM197
Biological: Pfs230D1-EPA
Other: Matrix-M
First Posted Date
2024-07-18
Last Posted Date
2025-08-17
Lead Sponsor
Serum Institute of India Pvt. Ltd.
Target Recruit Count
240
Registration Number
NCT06507605
Locations
🇲🇱

University of Science, Technique and Technology of Bamako (Usttb), Bamako, Mali

Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Phase 3
Recruiting
Conditions
Polio Immunization
Hepatitis B Immunization
Haemophilus Influenzae Type B Immunization
Tetanus Immunization
Diptheria Immunization
Pertussis Immunization
Interventions
Biological: Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV
Biological: Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV
First Posted Date
2024-05-14
Last Posted Date
2024-05-21
Lead Sponsor
Serum Institute of India Pvt. Ltd.
Target Recruit Count
1557
Registration Number
NCT06413121
Locations
🇧🇩

International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh

🇮🇳

Hamdard Institute of Medical Sciences and Research (HIMSR) with Centre for health research & Development, Society for applied studies, Hakeem Abdul Hameed Centenary Hospital (HAHCH), New Delhi, Delhi, India

🇮🇳

Manipal Academy of Higher Education, Manipal, Mangalore, Karnataka, India

and more 6 locations

Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years

Phase 3
Not yet recruiting
Conditions
Human Papillomavirus Infection
Interventions
Biological: Cervavac as two dose regimen
Biological: Cervavac as three dose regimen
Biological: Gardasil as three dose regimen
First Posted Date
2024-02-28
Last Posted Date
2025-01-07
Lead Sponsor
Serum Institute of India Pvt. Ltd.
Target Recruit Count
450
Registration Number
NCT06281119
Locations
🇰🇪

Centre For Clinical Research, Kemri, Nairobi, Kenya

🇰🇪

Partners in Health and Research Development (Phrd), Thika, Kenya

🇲🇿

Manhiça Health Research Center - Manhiça Foundation (CISM-FM), Manhiça, Mozambique

and more 1 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.